Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?

International Journal of Cardiology

Volumn 110, Issue 2, 2006, Pages 276-277

  Turhan, Hasan ^a   Yetkin, Ertan ^a  

^a INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Dyslipidemia; Fibrate; Metabolic syndrome

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; RISK REDUCTION;

ANTILIPEMIC AGENTS; CLOFIBRIC ACID; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X;

EID: 33747223647     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.11.027     Document Type: Article

References (15)

1. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
2. Turhan H., Yasar A.S., Basar N., Bicer A., Erbay A.R., and Yetkin E. High prevalence of metabolic syndrome among young women with premature coronary artery disease. Coron Artery Dis 16 (2005) 37-40
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. Y. Aizawa, N. Kamimura, H. Watanabe, Y. Aizawa, Y. Makiyama, Y. Usuda, et al., Cardiovascular risk factors are really linked in the metabolic syndrome: This phenomenon suggests clustering rather than coincidence. Int J Cardiol (in press).
5. Berneis K., and Rizzo M. LDL size: does it matter?. Swiss Med Wkly 134 (2004) 720-724
6. M. Rizzo, K. Berneis, Should we measure routinely the LDL peak particle size? Int J Cardiol (in press).
7. Packard C., Caslake M., and Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74 (2000) S17-S22
8. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
9. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. On behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
10. A. Onat, I. Sari, M. Yazici, G. Can, G,. Hergenc, Avci GS. Plasma triglycerides, an independent predictor of cardiovascular disease in men: A prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol (in press).
11. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
12. Jeppesen J., Hein H.O., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. Circulation 97 (1998) 1029-1036
13. Rubins H.B., Robins S.J., Collins D., et al. For the veterans affairs high-density lipoprotein cholesterol intervention trial study group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
14. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol on coronary heart disease risk in the Helsinki heart study. Circulation 85 (1992) 37-45
15. Rosenson R.S. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol 30 (2005) 241-279